QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
March 01 2023 - 8:00AM
Business Wire
- First partnership in the new QIAseq Platform Partnership to
increase compatibility of QIAGEN NGS kits with third-party digital
data-sharing and analytics companies
- Bringing together QIAGEN’s QIAseq reagent technology with
SOPHiA GENETICS DDM platform to expand compatibility with
data-driven medicine
- Collaboration to initially support somatic variant detection
using QIAseq panels for homologous recombination repair (HRR) and
subsequently for custom solutions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the launch of the new QIAseq Platform Partnership program
and the first partnership with medical data-analysis provider
SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its
QIAseq reagent technology for next-generation sequencing (NGS) with
the SOPHiA DDMTM digital analytics platform.
Building on its own offering integrated with QIAGEN Digital
Insights, the bioinformatics business of QIAGEN, the QIAseq
Platform Partnership program aims to enhance the utilization and
compatibility of its best-selling NGS kits to support secondary
analysis and tertiary interpretation workflows offered by other
digital data-sharing and analytics companies. These kits are
designed for use with any sequencer. The goal is to provide
research customers even wider access to the fast-growing area of
precision diagnostics that is producing new insights in
genetics.
As a first step in the new Platform Partnership program,
customers can now order QIAseq panels combined with SOPHiA DDM a
cloud-based platform that analyzes data from various sources to
enable entirely new research perspectives. The partnership will
initially support somatic variant detection (an alteration in DNA
that occurs after birth) using QIAseq Targeted DNA Pro panels for
homologous recombination repair (HRR), a special type of biomarker
test to find tumors that have certain mutations that may make them
sensitive to PARP inhibitors.
The partnership with SOPHiA GENETICS is planned to be expanded
to other areas of analysis, including the use of QIAseq panels
custom-made solutions.
“Our Platform Partnership Program will enable more customers to
benefit from the high quality of the QIAGEN NGS preparation kits
through the use of a wider range of analytics solutions to address
their unique analysis and interpretation needs,” said Thomas
Schweins, Senior Vice President of the Life Sciences Business Area
at QIAGEN. “SOPHiA GENETICS is our first partner thanks to their
unique expertise and reputation. We look forward to offering our
customers a leading combination and expanding our
collaboration.”
“SOPHiA’s mission is to democratize data-driven medicine. To get
there, we are partnering with reagent manufacturers so that our
deep expertise in genomic analysis complements their solutions,”
said Kevin Puylaert, Vice President Business Development at SOPHiA
GENETICS. “We have a strong and longstanding relationship with
QIAGEN and have used their products as part of our ‘bundle
solution’ for years. QIAGEN’s amplicon-targeted NGS technology has
an outstanding reputation to be among the best. We are taking full
advantage of the performance of both solutions in this
collaboration and are very optimistic about the positive impact on
medicine and research.”
The applications of SOPHiA DDM are planned to be expanded to
eventually support a wide range of applications using QIAGEN kits.
The goal is to allow customers to use SOPHiA’s Set-Up Program, an
efficient and reliable process that establishes and demonstrates
the analytical performance of any test prior to it being carried
out. This will enable customers to better and more efficiently
design new workflows using QIAseq technologies.
Some four million samples have been processed by QIAGEN’s
growing range of NGS panels. With leading products like QIAseq
Targeted DNA Pro and QIAseq Pan-cancer Multimodal panels, QIAGEN
has built a portfolio of universal NGS solutions that have enabled
customers to test for somatic cancer variants, tumor mutational
burden, minimal residual disease, and now with this partnership
homologous recombination repair deficiency.
Disclaimer: Unless specified otherwise, SOPHiA GENETICS products
are for research use only (RUO) and not for use in diagnostic
procedures. QIAseq Targeted DNA Panels are intended for molecular
biology applications. These products are not intended for the
clinical diagnosis, prevention or treatment of any disease.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing data-driven medicine as the standard for medical
care and life-sciences research. It is the creator of the SOPHiA
DDM™ Platform, a cloud-native platform capable of analyzing data
and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions.
For more information visit SOPHiAGENETICS.COM.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2022, QIAGEN employed approximately 6,200 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230301005632/en/
Investor Relations John Gilardi, +49 2103 29 11711 Phoebe
Loh, +49 2103 29 11457 e-mail: ir@QIAGEN.com Public
Relations Thomas Theuringer, +49 2103 29 11826 Daniela Eltrop,
+49 2103 29 11676 e-mail: pr@QIAGEN.com
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jul 2023 to Jul 2024